Key facts
- Cytomos’s last known valuation is $17.8M.
- It has raised $15.4M; the latest was Later Stage VC ($7.8M) in Oct 2024.
- Notable investors include Innovate UK, Scottish Enterprise, British Business Bank, Old College Capital, Archangel Investors.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cytomos
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytomos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytomos
Developer of a dielectric spectroscopy technology designed to assist with label-free cell analysis for biomedical research. The company's patented cell analysis technology ensures that every cell is analyzed, providing granular information on individual cells and the whole sample population, facilitates automated and quantitative sample assessment, phenotypic drug discovery, and stem cell therapy, enabling medical researchers to find functional endpoints that generate content fingerprints to prepare the right dose, thereby making cell-based diagnostics efficient.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2011
- Employees
- 32
- Website
- cytomos.com/
- Ownership
- Privately Held (backing)
Cytomos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytomos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytomos in its N-PORT filings yet. We sweep new filings monthly.